|
1
|
Arruebo M, Vilaboa N, Sáez-Gutierrez B,
Lambea J, Tres A, Valladares M and González-Fernández A: Assessment
of the evolution of cancer treatment therapies. Cancers.
3:3279–3330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Farkona S, Diamandis EP and Blasutig IM:
Cancer immunotherapy: The beginning of the end of cancer? BMC Med.
14:732016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coley WB: The treatment of malignant
tumors by repeated inoculations of erysipelas. With a report of ten
original cases. 1893. Clin Orthop Relat Res. 3–11. 1991.PubMed/NCBI
|
|
4
|
Parish CR: Cancer immunotherapy: The past,
the present and the future. Immunol Cell Biol. 81:106–113. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wiemann B and Starnes CO: Coley's toxins,
tumor necrosis factor and cancer research: A historical
perspective. Pharmacol Ther. 64:529–564. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Drake CG, Lipson EJ and Brahmer JR:
Breathing new life into immunotherapy: Review of melanoma, lung and
kidney cancer. Nat Rev Clin Oncol. 11:24–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo C, Manjili MH, Subjeck JR, Sarkar D,
Fisher PB and Wang XY: Therapeutic cancer vaccines: Past, present,
and future. Adv Cancer Res. 119:421–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Buonaguro L, Petrizzo A, Tornesello ML and
Buonaguro FM: Translating tumor antigens into cancer vaccines. Clin
Vaccine Immunol. 18:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rajput ZI, Hu SH, Xiao CW and Arijo AG:
Adjuvant effects of saponins on animal immune responses. J Zhejiang
Univ Sci B. 8:153–161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jones DE, Palmer JM, Burt AD, Walker C,
Robe AJ and Kirby JA: Bacterial motif DNA as an adjuvant for the
breakdown of immune self-tolerance to pyruvate dehydrogenase
complex. Hepatology. 36:679–686. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tovey MG and Lallemand C: Adjuvant
activity of cytokines. Methods Mol Biol. 626:287–309. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tefit JN and Serra V: Outlining novel
cellular adjuvant products for therapeutic vaccines against cancer.
Expert Rev Vaccines. 10:1207–1220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Petrovsky N and Aguilar JC: Vaccine
adjuvants: Current state and future trends. Immunol Cell Biol.
82:488–496. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schietinger A, Philip M, Liu RB, Schreiber
K and Schreiber H: Bystander killing of cancer requires the
cooperation of CD4(+) and CD8(+) T cells during the effector phase.
J Exp Med. 207:2469–2477. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim HJ and Cantor H: CD4 T-cell subsets
and tumor immunity: The helpful and the not-so-helpful. Cancer
Immunol Res. 2:91–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ramberg JE, Nelson ED and Sinnott RA:
Immunomodulatory dietary polysaccharides: A systematic review of
the literature. Nutr J. 9:542010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui L, Sun Y, Xu H, Cong H and Liu J: A
polysaccharide isolated from Agaricus blazei Murill (ABP-AW1) as a
potential Th1 immunity-stimulating adjuvant. Oncol Lett.
6:1039–1044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J and Sun Y: Structural analysis of an
alkali-extractable and water-soluble polysaccharide (ABP-AW1) from
the fruiting bodies of Agaricus blazei Murill. Carbohydrate
Polymers. 86:429–432. 2011. View Article : Google Scholar
|
|
20
|
Hartmann G, Marschner A, Viveros PR,
Stahl-Hennig C, Eisenblatter M, Suh YS, Endres S, Tenner-Racz K,
Uberla K, Racz P, et al: CpG oligonucleotides induce strong humoral
but only weak CD4+ T cell responses to protein antigens
in rhesus macaques in vivo. Vaccine. 23:3310–3317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sjölander A, van't Land B and Bengtsson
Lövgren K: Iscoms containing purified Quillaja saponins upregulate
both Th1-like and Th2-like immune responses. Cell Immunol.
177:69–76. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kawase O, Goo YK, Jujo H, Nishikawa Y and
Xuan X: Starfish, Asterias amurensis and Asterina pectinifera, as
potential sources of Th1 immunity-stimulating adjuvants. J Vet Med
Sci. 73:227–229. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mountford AP, Fisher A and Wilson RA: The
profile of IgG1 and IgG2a antibody responses in mice exposed to
Schistosoma mansoni. Parasite Immunol. 16:521–527. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Escors D: Tumour immunogenicity, antigen
presentation and immunological barriers in cancer immunotherapy.
New J Sci. 2014:7345152014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dubensky TW Jr and Reed SG: Adjuvants for
cancer vaccines. Semin Immunol. 22:155–161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Knutson KL and Disis ML: Tumor
antigen-specific T helper cells in cancer immunity and
immunotherapy. Cancer Immunol Immunother. 54:721–728. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Romagnani S: T-cell subsets (Th1 versus
Th2). Ann Allergy Asthma Immunol. 85:9–18. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X and Meng D: Innate endogenous
adjuvants prime to desirable immune responses via mucosal routes.
Protein Cell. 6:170–184. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun Y, Liu J, Yu H and Gong C: Isolation
and evaluation of immunological adjuvant activities of saponins
from the roots of Pulsatilla chinensis with less adverse
reactions. Int Immunopharmacol. 10:584–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shurin MR, Lu L, Kalinski P, Stewart-Akers
AM and Lotze MT: Th1/Th2 balance in cancer, transplantation and
pregnancy. Springer Semin Immunopathol. 21:339–359. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zamarron BF and Chen W: Dual roles of
immune cells and their factors in cancer development and
progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee PP, Zeng D, McCaulay AE, Chen YF,
Geiler C, Umetsu DT and Chao NJ: T helper 2-dominant antilymphoma
immune response is associated with fatal outcome. Blood.
90:1611–1617. 1997.PubMed/NCBI
|
|
35
|
Hu HM, Urba WJ and Fox BA: Gene-modified
tumor vaccine with therapeutic potential shifts tumor-specific T
cell response from a type 2 to a type 1 cytokine profile. J
Immunol. 161:3033–3041. 1998.PubMed/NCBI
|
|
36
|
Ghosh P, Komschlies KL, Cippitelli M,
Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH and Ochoa
AC: Gradual loss of T-helper 1 populations in spleen of mice during
progressive tumor growth. J Natl Cancer Inst. 87:1478–1483. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tzianabos AO: Polysaccharide
immunomodulators as therapeutic agents: Structural aspects and
biologic function. Clin Microbiol Rev. 13:523–533. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Honda-Okubo Y, Saade F and Petrovsky N:
Advax™, a polysaccharide adjuvant derived from delta
inulin, provides improved influenza vaccine protection through
broad-based enhancement of adaptive immune responses. Vaccine.
30:5373–5381. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Saade F, Honda-Okubo Y, Trec S and
Petrovsky N: A novel hepatitis B vaccine containing
Advax™, a polysaccharide adjuvant derived from delta
inulin, induces robust humoral and cellular immunity with minimal
reactogenicity in preclinical testing. Vaccine. 31:1999–2007. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Blankenstein T, Coulie PG, Gilboa E and
Jaffee EM: The determinants of tumour immunogenicity. Nat Rev
Cancer. 12:307–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chaplin DD: Overview of the immune
response. J Allergy Clin Immunol. 125 Suppl 2:S3–S23. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Serrano-Villar S, Sainz T, Lee SA, Hunt
PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue
PY, et al: HIV-infected individuals with low CD4/CD8 ratio despite
effective antiretroviral therapy exhibit altered T cell subsets,
heightened CD8+ T cell activation, and increased risk of
non-AIDS morbidity and mortality. PLoS Pathog. 10:e10040782014.
View Article : Google Scholar : PubMed/NCBI
|
